Compare LFST & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | DAWN |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2021 | 2021 |
| Metric | LFST | DAWN |
|---|---|---|
| Price | $6.34 | $21.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $9.71 | ★ $26.00 |
| AVG Volume (30 Days) | 2.5M | ★ 6.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,424,285,000.00 | $158,182,000.00 |
| Revenue This Year | $17.18 | $55.03 |
| Revenue Next Year | $14.02 | $28.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.85 | ★ 20.60 |
| 52 Week Low | $3.74 | $5.64 |
| 52 Week High | $8.09 | $21.46 |
| Indicator | LFST | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 81.44 |
| Support Level | $6.16 | $10.30 |
| Resistance Level | $6.63 | N/A |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 12.34 | 79.55 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.